Do PRP Injections Work for Thumb Arthritis? What the Research Shows
- 2 days ago
- 6 min read
By Dr. Jeffrey Peng, MD · Published March 5, 2026 · 8 min read
Watch the Full Video
Thumb arthritis is one of the most common — and underappreciated — causes of hand pain and disability. The carpometacarpal (CMC) joint at the base of the thumb bears tremendous load throughout the day: opening jars, turning keys, gripping a pen, pinching small objects. When osteoarthritis develops at this joint, even routine tasks become painful and limiting.
Traditional treatments such as splinting, anti-inflammatory medications, and cortisone injections often provide only temporary relief. Many patients in my practice ask whether platelet-rich plasma (PRP) injections offer a better, longer-lasting option. In this post, I review the available clinical evidence on PRP for thumb CMC arthritis, compare it directly to cortisone, and share my recommended approach for patients seeking more durable relief.
What Is Thumb CMC Joint Arthritis?
The thumb CMC joint — also known as the trapeziometacarpal (TMC) joint — sits at the base of the thumb where the first metacarpal bone meets the trapezium bone of the wrist. This saddle-shaped joint enables the wide range of thumb movement required for virtually every gripping and pinching task. That same mechanical versatility also makes it one of the most commonly affected joints in osteoarthritis, particularly in women over age 50.
Symptoms include pain and tenderness at the thumb base, reduced grip and pinch strength, instability with pinching motions, and difficulty with activities that require sustained manual force. The clinical consequences are not trivial: patients frequently report difficulty opening containers, turning keys, writing for extended periods, or performing fine motor tasks at work. Despite affecting a small joint, thumb CMC arthritis can meaningfully impair quality of life.
Why Cortisone Injections Fall Short
Corticosteroid injections are commonly offered as a first-line injectable treatment for thumb CMC arthritis, and they can provide meaningful short-term symptom relief. However, the durability of benefit is limited — typically lasting weeks to a few months — and the risks of repeated injections are increasingly recognized.
Research in the knee and hip has shown that cortisone injections are associated with accelerated cartilage loss and, in some cases, a condition called rapidly progressive joint disease. While the thumb CMC joint is not weight-bearing in the conventional sense, the potential for corticosteroids to damage the articular environment is a real concern, particularly when injections are repeated over time. For patients with mild to moderate disease who still have viable cartilage, it is critical to avoid treatments that may worsen the very condition we are managing.
How Does PRP Work?
Platelet-rich plasma is produced by drawing a sample of the patient's own blood, centrifuging it to concentrate the platelet-rich layer, and injecting that concentrate directly into the affected joint. Platelets contain alpha granules loaded with growth factors — including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), insulin-like growth factor (IGF-1), and vascular endothelial growth factor (VEGF) — as well as anti-inflammatory cytokines such as interleukin-1 receptor antagonist (IL-1ra).
When introduced into an arthritic joint, these bioactive molecules help shift the internal joint environment from a pro-inflammatory, destructive state toward a more balanced one. In knee osteoarthritis, clinical studies have documented measurable reductions in inflammatory markers including TNF-alpha and IL-1 beta at six months following PRP treatment. This biological mechanism supports not only symptom relief but also the potential for disease modification — slowing the underlying arthritis rather than simply masking its symptoms.
What Does the Research Show for PRP in Thumb Arthritis?
The evidence base for PRP in thumb CMC arthritis remains small, but what exists is consistently encouraging. The most significant study is a prospective randomized controlled trial by Malahias et al. that enrolled 33 patients with Eaton-Littler grade I–III thumb CMC arthritis. Participants were randomized to two ultrasound-guided PRP injections or two corticosteroid injections, administered two weeks apart. Patients were assessed with visual analog scale (VAS) pain scores and Q-DASH functional questionnaires at baseline, three months, and twelve months.
At three months, both groups showed significant improvement compared to their respective baselines — cortisone and PRP appeared roughly equivalent in early pain relief. At twelve months, the picture changed substantially: the PRP group continued to demonstrate significant improvements in pain (P = 0.015) and function (P = 0.025), while the cortisone group had returned to near-baseline levels. Patient satisfaction at twelve months was dramatically higher in the PRP group — approximately 70% — compared to just 13% in the cortisone group (P = 0.002).
A smaller pilot study of ten patients evaluated two PRP injections spaced four weeks apart using leukocyte-reduced PRP. At six-month follow-up, VAS pain scores improved significantly, though DASH scores did not reach statistical significance — almost certainly a reflection of the very small sample size rather than absence of effect. No significant adverse events occurred. While this pilot cannot support firm conclusions on its own, it corroborates the safety and directional efficacy seen in the larger RCT.
Interpreting the Evidence in Context
The most important critique of the current thumb CMC PRP literature is the limited number of patients studied. Small samples make it difficult to generalize findings, and neither study reported detailed platelet counts or concentrations, which limits our ability to assess PRP quality and dosing. These are legitimate scientific limitations.
However, the pattern of results — durable benefit for PRP versus short-lived relief with cortisone — is consistent with what has been observed across a much larger evidence base in other indications. PRP has demonstrated long-term superiority over cortisone in well-powered trials of knee osteoarthritis, lateral epicondylitis (tennis elbow), medial epicondylitis (golfer's elbow), plantar fasciitis, and gluteal tendinopathy. The thumb CMC data fits a coherent biological and clinical pattern, which provides reasonable confidence in extending PRP to this indication.
Does PRP Slow the Progression of Arthritis?
One of the most compelling reasons to consider PRP over cortisone is its potential to modify the disease — not simply control symptoms. A randomized clinical trial in knee osteoarthritis demonstrated that pure platelet-rich plasma was superior to sham saline in sustaining at least 24 months of symptom relief and was associated with slowing of arthritis progression. Across the knee OA literature, PRP has been associated with up to a 50% reduction in the rate of radiographic arthritis progression over five years compared to placebo.
The mechanism involves a reduction in key pro-inflammatory cytokines — particularly TNF-alpha and IL-1 beta — which drive cartilage breakdown in osteoarthritis. By modulating this inflammatory environment, PRP may help preserve residual cartilage over time. For patients with mild to moderate thumb CMC arthritis, this disease-modifying potential is an important part of the clinical rationale for PRP as a preferred injectable treatment.
Why Platelet Dose Matters
A critical point that many physicians and patients overlook is that not all PRP preparations are equivalent. Just as dosing matters in every other area of medicine, platelet dose and concentration have a direct impact on PRP outcomes.
The knee osteoarthritis literature has established a clear dose-response relationship: low-dose PRP preparations — those delivering fewer than approximately 5 billion platelets — produce outcomes no better than placebo, while preparations delivering 5 to 10 billion platelets or more produce significantly superior results. Many commercially available PRP systems yield only 1–2 billion platelets per treatment, which the evidence would classify as subtherapeutic. When patients tell me their PRP injections did not work, the first question I ask is about the blood draw volume and preparation method. Inadequate platelet dosing is the most common explanation for PRP treatment failure.
My Recommended Approach for Thumb CMC Arthritis
For patients with mild to moderate thumb CMC osteoarthritis seeking injection therapy, my preference is to proceed with PRP rather than cortisone — particularly for patients who want durable relief, have active occupational or recreational demands on their hands, or who are interested in addressing the underlying disease rather than simply suppressing short-term inflammation.
My standard protocol involves a 30 mL blood draw, which typically yields approximately 5–6 billion platelets concentrated to approximately 1 mL. This is delivered under ultrasound guidance as an intra-articular injection into the CMC joint. In my experience, this dose produces meaningful pain relief and functional improvement that can last up to one year in patients with mild to moderate arthritis. I have also seen encouraging results in grade IV (bone-on-bone) disease, though these patients tend to require more frequent treatments to sustain their benefit.
What patients do in the days and weeks before and after a PRP injection is equally important. Factors such as anti-inflammatory medication use, activity level, and timing of the injection can significantly affect outcomes. I discuss these optimization strategies during every consultation.
References
1. Malahias MA, Roumeliotis L, Nikolaou VS, Chronopoulos E, Sourlas I, Babis GC. Platelet-rich plasma versus corticosteroid intra-articular injections for the treatment of trapeziometacarpal arthritis: a prospective randomized controlled clinical trial. Cartilage. 2021;12(1):51–61. doi:10.1177/1947603518805230
2. Ruegg TA, Bohm J, Haefeli PC, et al. Leukocyte-reduced platelet-rich plasma treatment of basal thumb arthritis: a pilot study. Case Rep Orthop. 2016;2016:9262909. doi:10.1155/2016/9262909
3. Chu J, Duan W, Yu Z, et al. Intra-articular injections of platelet-rich plasma decrease pain and improve functional outcomes than sham saline in patients with knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2022;30(12):4063–4071. doi:10.1007/s00167-022-06887-7
Medical Disclaimer: This content is for educational purposes only and does not substitute for the medical advice of a physician. Always consult your healthcare provider before beginning any new treatment program. The information presented reflects the opinion of Dr. Jeffrey Peng and does not represent the views of his employers or affiliated hospital systems.
Comments